MNE-C261: off-the-shelf mRNA vaccine for MSS colorectal cancer
myNEO's lead internal program is an off-the-shelf mRNA-LNP vaccine targeting camyotopes in microsatellite-stable colorectal cancer (MSS-CRC). As of August 2026, the program is in preclinical development, with clinical initiation targeted for Q4 2027.
MNE-C261: mRNA-LNP vaccine
We are advancing MNE-C261 in MSS-CRC to the clinic with the aim of initiating the clinical phase by Q4 2027. myNEO is working toward initiation of a first Phase I/IIa trial.
- 26 CRC-specific camyotope targets
- Strong polyfunctional immunogenicity
- Very high target abundance: up to 99%
- Exceptional coverage: more than 95%
- Broad HLA-coverage: more than 95%
| Program | Disease | Therapy | Target | Pre-clinical | Phase 1 | Phase 2 |
|---|---|---|---|---|---|---|
| MNE-C261 | MSS-CRC | Off-the-shelf mRNA | Camyotopes | |||
| MNE-CXX2 | TNBC | Off-the-shelf mRNA | Camyotopes | |||
| MNE-CXX3 | PAAD | Off-the-shelf mRNA | Camyotopes | |||
| MNE-P201 | Solid tumors | Personalized mRNA | Neoantigens | |||
MNE-C261 targets camyotopes, proprietary dark-genome tumor antigens for off-the-shelf immunotherapies. See the full pipeline and assets page for partnered programs and the antigen target library.
What is MNE-C261?
MNE-C261 is myNEO's lead internal program: an off-the-shelf mRNA-LNP vaccine targeting camyotopes in microsatellite-stable colorectal cancer (MSS-CRC). The design includes 26 CRC-specific camyotope targets.
What is the development status of MNE-C261?
As of August 2026, MNE-C261 is in preclinical development. myNEO is working toward initiation of a first Phase I/IIa trial, with clinical initiation targeted for Q4 2027.
What preclinical characteristics are reported for MNE-C261?
Reported preclinical characteristics for the program include strong polyfunctional immunogenicity, target abundance up to 99%, population coverage of more than 95%, and broad HLA coverage of more than 95%.
Talk to our team
Discuss partnerships, licensing, or myNEO's internal pipeline.